phone

Amyloidosis - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 157
  • Category: Pharmaceuticals
  • Country: Global
Amyloidosis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Amyloidosis - Overview 6
Amyloidosis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Amyloidosis - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Amyloidosis - Companies Involved in Therapeutics Development 23
Alnylam Pharmaceuticals Inc 23
Amgen Inc 23
Arcturus Therapeutics Inc 24
Bsim2 24
Celgene Corp 25
GlaxoSmithKline Plc 25
Ionis Pharmaceuticals Inc 26
Johnson & Johnson 26
Millennium Pharmaceuticals Inc 27
Neurimmune Holding AG 27
Novartis AG 28
Oncopeptides AB 28
Pfizer Inc 29
Prothena Corp Plc 29
R Pharm 30
Regeneron Pharmaceuticals Inc 30
SOM Biotech SL 31
Spectrum Pharmaceuticals Inc 31
Amyloidosis - Drug Profiles 32
AG-10 - Drug Profile 32
ALN-ANG - Drug Profile 33
ALN-TTRsc02 - Drug Profile 34
CAEL-101 - Drug Profile 35
canakinumab - Drug Profile 37
carfilzomib - Drug Profile 43
CLR-01 - Drug Profile 55
daratumumab - Drug Profile 57
dezamizumab - Drug Profile 73
dezamizumab + GSK-2315698 - Drug Profile 74
doxycycline hyclate - Drug Profile 75
EDE-1307 - Drug Profile 76
GSK-2315698 - Drug Profile 77
GSK-3039294 - Drug Profile 78
inotersen sodium - Drug Profile 79
ixazomib citrate - Drug Profile 83
LUNAR-TTR - Drug Profile 93
melphalan - Drug Profile 94
melphalan flufenamide - Drug Profile 98
Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile 100
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile 101
NEOD-001 - Drug Profile 102
NI-301 - Drug Profile 107
NPT-289 - Drug Profile 108
Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile 109
patisiran - Drug Profile 110
pomalidomide - Drug Profile 118
PRX-004 - Drug Profile 125
RPH-104 - Drug Profile 126
Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimers Disease and Amyloidosis - Drug Profile 127
Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile 128
Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile 129
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile 130
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile 131
tafamidis meglumine - Drug Profile 132
tolcapone - Drug Profile 135
Amyloidosis - Dormant Projects 137
Amyloidosis - Discontinued Products 138
Amyloidosis - Product Development Milestones 139
Featured News & Press Releases 139
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 153
Disclaimer 154

List Of Tables


Number of Products under Development for Amyloidosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Amgen Inc, H2 2017
Amyloidosis - Pipeline by Arcturus Therapeutics Inc, H2 2017
Amyloidosis - Pipeline by Bsim2, H2 2017
Amyloidosis - Pipeline by Celgene Corp, H2 2017
Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2017
Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Johnson & Johnson, H2 2017
Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2017
Amyloidosis - Pipeline by Novartis AG, H2 2017
Amyloidosis - Pipeline by Oncopeptides AB, H2 2017
Amyloidosis - Pipeline by Pfizer Inc, H2 2017
Amyloidosis - Pipeline by Prothena Corp Plc, H2 2017
Amyloidosis - Pipeline by R Pharm, H2 2017
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by SOM Biotech SL, H2 2017
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Amyloidosis - Dormant Projects, H2 2017
Amyloidosis - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Amyloidosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Amyloidosis - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline

View Report

Amyloidosis Global Clinical Trials Review, H1, 2017 GlobalDatas clinical trial report, Amyloidosis Global Clinical Trials Review, H1, 2017 provides an overview of Amyloidosis clinical trials scenario. This report provides top line

View Report

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrades Disease) -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrades

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports